Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease

Proceedings of the American Thoracic Society

Volumn 2, Issue 4, 2005, Pages 297-304

  Belmonte, Kristen E ^a,b  

^a GLAXOSMITHKLINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Airway hyperresponsiveness; Bronchodilator therapy; Muscarinic receptors; Parasympathetic nerves

Indexed keywords

ATROPINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; OXITROPIUM BROMIDE; PHOSPHODIESTERASE IV INHIBITOR; SCOPOLAMINE; TIOTROPIUM BROMIDE;

ACETYLCHOLINE RELEASE; ASTHMA; BREATHING MUSCLE; BRONCHOSPASM; CARDIOTOXICITY; CHOLINERGIC SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; HUMAN; LUNG; NONHUMAN; PARASYMPATHETIC NERVE; SMOOTH MUSCLE; VAGUS NERVE STIMULATION; XEROSTOMIA;

ADMINISTRATION, INHALATION; BRONCHIAL HYPERREACTIVITY; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; LUNG; PARASYMPATHETIC NERVOUS SYSTEM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, MUSCARINIC;

EID: 27644530096     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200504-043SR     Document Type: Conference Paper

References (94)

1. Colebatch HJH, Halmagyi DFJ. Effect of vagotomy and vagal stimulation on lung mechanics and circulation. J Appl Physiol 1963;18:881-887.
2. Baker B, Peatfield AC, Richardson PS. Nervous control of mucin secretion into human bronchi. J Physiol 1985;365:297-305.
3. Laitinen LA, Laitinen MV, Widdicombe JG. Parasympathetic nervous control of tracheal vascular resistance in the dog. J Physiol 1987;385:135-146.
4. 1) muscarinic receptors in vagally mediated bronchoconstriction in humans. Am Rev Respir Dis 1989;139:446-449.
5. Fryer AD, MacLagan J. Muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1984;83:973-978.
6. van Koppen CJ, Blankesteijn WM, Klaassen ABM, Rodrigues de Miranda JF, Beld AJ, van Ginneken CAM. Autoradiographic visualization of muscarinic receptors in pulmonary nerves and ganglia. Neurosci Lett 1987;83:237-240.
7. Mak JCW, Barnes PJ. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis 1990;141:1559-1568.
8. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984;311:421-425.
9. O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnusser H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-840.
10. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542-549.
11. Willemse BWM, Postma DS, Timens W, ten Hacken NHT. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004;23:464-476.
12. Caulfield MP, Birdsall NJM. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279-290.
13. 2 receptors in bovine tracheal smooth muscle: discrepancies between binding and function. Eur J Pharmacol 1988;153:73-82.
14. Jones CA, Madison JM, Tom-Moy M, Brown JK. Muscarinic cholinergic inhibition of adenylate cyclase in airway smooth muscle. Am J Physiol 1987;253:C97-C104.
15. Ca channels in smooth muscle cells by a pertussis-sensitive G protein. Am J Physiol 1991;261:C1204-C1209.
16. Torphy TJ. β-Adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. Trends Pharmacol Sci 1994;15:370-374.
17. 3-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. Am J Physiol Regul Integr Comp Physiol 2002;282:R1443-R1449.
18. 3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J Neurosci 2002;22:10627-10632.
19. Faulkner D, Fryer AD, MacLagan J. Postganglionic muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1986;88:181-187.
20. Fryer AD, Jacoby DB. Muscarinic receptors and control of airway smooth muscle. Am J Respir Crit Care Med 1998;158:S154-S160.
21. Blaber LC, Fryer AD, MacLagan J. Neuronal muscarinic receptors attenuate vagally-induced contraction of feline bronchial smooth muscle. Br J Pharmacol 1985;6:723-728.
22. Ashe JH, Yarosh CA. Differential and selective antagonism of the slow-inhibitory postsynaptic potential and slow-excitatory postsynaptic potential by gallamine and pirenzepine in the superior cervical ganglion of the rabbit. Neuropharmacology 1984;23:1321-1329.
23. Yang Z-J, Biggs DF. Muscarinic receptors and parasympathetic neuro-transmission in guinea-pig trachea. Eur J Pharmacol 1991;193:301-308.
24. 1 receptors mediate the increase in pulmonary resistance during vagus nerve stimulation in dogs. Am Rev Respir Dis 1987;136:1135-1139.
25. 2+ current and M current in rat sympathetic neurons. Proc Natl Acad Sci USA 1992;89:9544-9548.
26. 1-selective muscarinic receptor antagonist (pirenzepine) on basal bronchomotor tone in young women. Respiration (Herrlisheim) 1992;59:102-106.
27. Ceyhan B, Çelikel T, Simsir S, Kandemir B. Comparison of the bronchodilator efficacy of nebulized pirenzepine and ipratropium bromide in patients with airway obstructive lung disease. Int J Clin Pharmacol Ther Toxicol 1993;31:510-513.
28. 1 muscarinic receptors in pulmonary sympathetic nerves in the guinea-pig by use of pirenzepine. Br J Pharmacol 1989;97:499-505.
29. Skoogh B-E. Parasympathetic ganglia in the airways. Bull Eur Physiopathol Respir 1986;22:143-147.
30. Hey C, Wessler I, Racké K. Muscarinic inhibition of endogenous noradrenaline release from rabbit isolated trachea: receptor subtype and receptor reserve. Naunyn Schmiedebergs Arch Pharmacol 1994;350:464-472.
31. Nathanson I, Nadel JA. Movement of electrolytes and fluid across airways. Lung 1984;162:125-137.
32. Sasaki T, Shimura S, Ikeda K, Sasaki H, Takishima T. Sodium efflux from isolated submucosal gland in feline trachea. Am J Physiol 1990;258:L112-L117.
33. Mak JCW, Baraniuk JN, Barnes PJ. Localization of muscarinic receptor subtype mRNAs in human lung. Am J Respir Cell Mol Biol 1992;7:344-348.
34. 5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 2003;28:437-442.
35. Yang CM, Farley JM, Dwyer TM. Muscarinic stimulation of submucosal glands in swine trachea. J Appl Physiol 1988;64:200-209.
36. Greenberg B, Rhoden K, Barnes PJ. Endothelium-dependent relaxation of human pulmonary arteries. Am J Physiol 1987;252:H434-H438.
37. Walch L, Brink C, Norel X. The muscarinic receptor subtypes in human blood vessels. Therapie 2001;56:223-226.
38. Barnes PJ. Mechanisms in COPD. Chest 2000;117:10S-14S.
39. Barnes PJ, Belvisi MG, Mak JCW, Haddad E-B, O'Connor B. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 1995;56:853-859.
40. Whicker SD, Armour CL, Black JL. Responsiveness of bronchial smooth muscle from asthmatic patients to relaxant and contractile agonists. Pulm Pharmacol 1988;1:25-31.
41. van Koppen CJ, Rodrigues De Miranda JF, Beld AJ, van Ginneken CAM, Lammers J-WJ, van Herwaarden CLA. Muscarinic receptor sensitivity in airway smooth muscle of patients with obstructive airway disease. Arch Int Pharmacodyn Ther 1988;295:238-244.
42. Costello RW, Evans CM, Yost BL, Belmonte KE, Gleich GJ, Jacoby DB, Fryer AD. Antigen-induced hyperreactivity to histamine: role of the vagus nerves and eosinophils. Am J Physiol 1999;276:L709-L714.
43. 2 muscarinic receptor dysfunction. J Appl Physiol 1998;85:1708-1718.
44. 2 receptor dysfunction. Am J Physiol Lung Cell Mol Physiol 2000;279:L477-L486.
45. Whicker SD, Compton MR, Seale JP, Black JL. Effect of sensitization and aerosol antigen challenge in guinea-pigs: studies of airway receptor function and characteristics. Pulm Pharmacol 1990;3:129-136.
46. Haddad E-B, Mak JCW, Belvisi MG, Nishikawa M, Rousell J, Barnes PJ. Muscarinic and β-adrenergic receptor expression in peripheral lung from normal and asthmatic patients. Am J Physiol 1996;270:L947-L953.
47. Donfack J, Kogut P, Forsythe S, Solway J, Ober C. Sequence variation in the promoter region of the cholinergic receptor muscarinic 3 gene and asthma and atopy. J Allergy Clin Immunol 2003;111:527-532.
48. 2 muscarinic receptor function in the lung. Life Sci 1999;64:449-455.
49. Minette PAH, Lammers J-WJ, Dixon CMS, McCusker MT, Barnes PJ. A muscarinic agonist inhibits reflex bronchoconstriction in normal but not in asthmatic subjects. J Appl Physiol 1989;67:2461-2465.
50. 2 muscarinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1320-1325.
51. Foster WM, Brown RH, Macri K, Mitchell CS. Bronchial reactivity of healthy subjects: 18-20 h postexposure to ozone. J Appl Physiol 2000;89:1804-1810.
52. Peel JL, Tolbert PE, Klein M, Metzger KB, Flanders WD, Todd K, Mulholland JA, Ryan PB, Frumkin H. Ambient air pollution and respiratory emergency department visits. Epidemiology 2005;16:164-174.
53. 2 muscarinic receptors by eosinophil major basic protein. J Appl Physiol 1999;87:1272-1278.
54. 2 muscarinic receptor function. J Appl Physiol 1994;76:1088-1097.
55. 2 receptor. J Clin Invest 1993;91:1314-1318.
56. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, MacCallum P, Meade TW, Jeffries DJ, Johnston SL, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-1623.
57. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, O'Toole S, Myint SH, Tyrrell DAJ, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995;310:1225-1229.
58. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993;307:982-986.
59. Empey DW, Laitinen LA, Jacobs L, Gold WM, Nadel JA. Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. Am Rev Respir Dis 1976:113:131-139.
60. Peterson GL, Rosenbaum LC, Broderick DJ, Schimerlik ML. Physical properties of the purified cardiac muscarinic acetylcholine receptor. Biochemistry 1986;25:3189-3202.
61. Scheid A, Caliguiri LA, Compans RW, Choppin PW. Isolation of paramyxovirus glycoproteins: association of both hemagglutinating and neuraminidase activities with the larger SV5 glycoprotein. Virology 1972;50:640-652.
62. Boulan ER, Pendergast M. Polarized distribution of viral envelope proteins in the plasma membrane of infected epithelial cells. Cell 1980;20:45-54.
63. 2 muscarinic acetylcholine receptors. Biochem Biophys Res Commun 1988;150:673-680.
64. 2 muscarinic receptor dysfunction. Am J Physiol Lung Cell Mol Physiol 2004;286: L1255-L1259.
65. 2 muscarinic receptor dysfunction. Am J Respir Crit Care Med 2003;167:550-556.
66. 2 muscarinic receptor dysfunction. J Appl Physiol 2002;92:1417-1422.
67. 2 muscarinic receptor function and gene expression in cultured airway parasympathetic neurons. J Clin Invest 1998;102:242-248.
68. 2 muscarinic receptor function in antigen-challenged guinea pigs. Am J Respir Cell Mol Biol 1995;12:320-328.
69. 2 muscarinic receptors in antigen-challenged guinea pig airways. J Clin Invest 1997;99:2036-2044.
70. 2 muscarinic receptor function. Am J Physiol 1997;273:L93-103.
71. Fryer AD, Jacoby DB. Function of pulmonary M2 muscarinic receptors in antigen-challenged guinea pigs is restored by heparin and poly-L-glutamate. j Clin Invest 1992;90:2292-2298.
72. Miraldi E, Masti A, Ferri S, Barni Comparini I. Distribution of hyoscyamine and scopolamine in Datura stramonium. Fitoterapia 2001;72:644-648.
73. Charpin D, Orehek J, Velardocchio JM. Bronchodilator effects of antiasthmatic cigarette smoke (Datura stramonium). Thorax 1979;34:259-261.
74. Salter HH. Asthmatic paroxysm: treatment by sedatives. In: On asthma: its pathology and treatment. London: John Churchill; 1860. pp. 134-144.
75. Waters ATM. Researches on the nature, pathology and treatment of emphysema of the lungs. London: Churchill; 1862.
76. Fothergill JM. Chronic bronchitis: its form and treatment. London: Baillière Tindall; 1882.
77. Tramontana JA, Marderosian AH. Anti-asthmatic drugs as hallucinogens. Pa Med 1967;70:58-60.
78. Petrie GR, Palmer KN. Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma. BMJ 1975;1:430-432.
79. Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS. Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs 1980;20:237-266.
80. Flohr E, Bischoff KO. Oxitropium bromide, a new anticholinergic drug, in a dose-response and placebo comparison in obstructive airway diseases. Respiration (Herrlisheim) 1979;38:98-104.
81. Disse B, Speck GA, Rominger KL, Witek TJ Jr, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-464.
82. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276.
83. Borg GAV. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-381.
84. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-758.
85. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance in patients with COPD. Chest 2003;123:1810-1816.
86. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224.
87. van Noord JA, Smeets JJ, Custers FL, Korducki L, Cornelissen PJ. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002;19:639-644.
88. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-1327.
89. Vincken W, van Noord JA, Greefhorst APM, Bantje TA, Kesten S, Korducki L, Cornelissen PJG, on behalf of the Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-216.
90. Lopez-Vidriero MT, Costello J, Clark TJ, Das I, Keal EE, Reid L. Effect of atropine on sputum production. Thorax. 1975;30:543-547.
91. Taylor RG, Pavia D, Agnew JE, Lopez-Vidriero MT, Newman SP, Lennard-Jones T, Clarke SW. Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance. Thorax 1986;41:295-300.
92. Disse B. Antimuscarinic treatment for lung diseases: from research to clinical practice. Life Sci 2001;68:2557-2564.
93. Tamaoki J, Chiyotani A, Tagaya E, Sakai N, Konno K. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax 1994;49:545-548.
94. Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr; U.S. Tiotropinm Study Group. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 2000;118:1294-1302.